Langsted et al. [
[1]
] estimated the extent of undertreatment and overtreatment with cholesterol-lowering
therapy according to the European guidelines in a Danish population-based cohort without
ischemic cardiovascular disease (CVD) and diabetes (n = 92.348; age 35–100 years).
Eligibility and goals for guideline-recommended therapy were assessed in everyone
based on 10-year risk for fatal CVD, determined from the European SCORE chart and
LDL-cholesterol level. Definite undertreatment was found in 19% and definite overtreatment
in 0.2% of cases, leading to the statement that ”the data clearly show that undertreatment with cholesterol-lowering therapy is a major
problem, while overtreatment at most is a minor issue.”Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 danes without ischemic cardiovascular disease and diabetes in 2004-2014.Atherosclerosis. 2016; 257: 9-15
- ESC/EAS guidelines for the management of dyslipidaemias.Eur. Heart J. 2011; 32: 1769-1818
- European guidelines on cardiovascular disease prevention in clinical practice (version 2012).Atherosclerosis. 2012; 223: 1-68
- 2016 European guidelines on cardiovascular disease prevention in clinical practice.Atherosclerosis. 2016; 252: 207-274
- Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention.Eur. Heart J. Dec 2016; (online) (doi: http://dx.doi.org/10.1093/eurheartj/ehw568)
- ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans.Eur. Heart J. Nov 2016; (online) (doi: https://doi.org/10.1093/eurheartj/ehw426)
Article info
Publication history
Published online: February 15, 2017
Accepted:
February 9,
2017
Received:
January 31,
2017
Identification
Copyright
© 2017 Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004–2014AtherosclerosisVol. 257
- Reply to: “Appropriate use of cholesterol-lowering therapy”AtherosclerosisVol. 262
- PreviewWe thank Erling Falk for his interest in our work, the insightful comments and his suggestions to improve our analyses. We agree that there are several limitations with the current European guidelines [1,2]; however, addressing them was not directly within the scope of the present article. By simply applying the guidelines as they are, we estimated the extent of undertreatment and overtreatment with cholesterol-lowering therapy according to the European guidelines in individuals of the Danish general population without ischemic cardiovascular disease and diabetes [3].
- Full-Text
- Preview
